Table 5.
Major Drug Resistance Mutations and Multiclass Resistance Profiles in Human Immunodeficiency Virus–Positive HOPE Donors
| Donors | Major DRMs | |||
|---|---|---|---|---|
| NRTIs | NNRTIs | PIs | INSTIs | |
| All detected DRMs (n = 20 [42%])a | (n = 9 [19%]) | (n = 16 [33%]) | (n = 1 [2%]) | (n = 2 [4%]) |
| M184V/I (n = 5), D67N/G/E/H/S/T (n = 2),M41L,A62V, K65R/N/E,L74V/I, T215Y/F/C/D | K103N/S/H/T/R/Q/E (n = 8), V179D/E/F/I/L/T (n = 6), V108I (n = 2), L100I/V,K101E/H/P/Q/R/N, V106A/M/I, Y181C/I/V/S/G | L90M | T66A/I/K, E92Q/G/V, Y143Y/C | |
| Donors with multiclass DRMs (n = 6 [13%]) | ||||
| Donor 1 (ART: ABC/3TC/DTG; VL: <40 copies/mL) | A62V, K65N | L100I, V108I, V179I | … | … |
| Donor 2 (ART: TAF/FTC/EVG/c; VL: 51 827 copies/mL) | M184I | K103N | … | … |
| Donor 3 (ART: TAF/FTC + DRV/c; VL: <40 copies/mL) | M184V | V179I | L90M | … |
| Donor 4 (ART: TDF/FTC + DTG + ATV/r; VL: <40 copies/mL) | M41L, M184V, T215C/Y | K103N | … | Y143C |
| Donor 5 (ART: TDF/FTC/EFV + DRV/r; VL: 1905 copies/mL) | M184V/I | … | … | T66I,E92Q |
| Donor 6 (ART: TAF/FTC/BIC; VL: <40 copies/mL) | D67N | K103N | … | … |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; BIC, bictegravir; c, cobicistat; DRMs, drug resistance mutations; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; HOPE, HIV Organ Policy Equity; INSTIs, integrase strand transfer inhibitors; NNRTIs, nonnucleoside reverse-transcriptase inhibitors; NRTIs, nucleoside reverse-transcriptase inhibitors; PIs, protease inhibitors; r, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; VL, viral load (for human immunodeficiency virus).
aA total of 48 human immunodeficiency virus–positive donors had available genotype data, with 47 interpretable laboratory genotypes and 14 historical genotypes, which were combined. Mutations were reported on only 1 donor genotype unless otherwise specified in parentheses.